Ernexa Therapeutics Inc. — Form 10-Q

Ernexa Therapeutics adopted Fourth Amended and Restated Bylaws effective August 4, 2026. The filing is a boilerplate governance document containing standard corporate provisions: stockholder meeting procedures (120–90 day notice window for proposals), director election and removal (majority vote, no staggered board), board quorum (majority of whole board), committee structure, officer roles, indemnification (maximum Delaware law), exclusive Delaware/federal forum for disputes, and amendment procedures (majority board or stockholder vote). No specific dollar amounts, transactions, counterparties, or material business changes are disclosed. This is a routine corporate governance filing.